Identity
PE-22-28 is a shortened, stabilised derivative of spadin. Spadin itself is a natural peptide — a fragment of the sortilin propeptide — that blocks the TREK-1 background potassium channel. PE-22-28 keeps that channel-blocking activity in a smaller, more metabolically stable form. It is a defined synthetic peptide, not a blend, and belongs to the neuro/antidepressant research class rather than the tissue-repair or metabolic families.
The target, and why it is interesting
TREK-1 is a two-pore-domain (K2P) potassium channel that sets neuronal excitability. The reason it matters here is genetic: TREK-1 knockout mice are resistant to depression in standard models. That makes the channel a rational antidepressant target — if deleting it confers resistance, blocking it pharmacologically might reproduce the effect. Spadin was the natural blocker that proved the concept; PE-22-28 is the engineered attempt to make a more drug-like version. The logic is unusually clean for a research peptide — a specific channel, a knockout phenotype, and a molecule aimed straight at it.
What the evidence shows
In rodent models from the originating French programme (Borsotto, Mazella and colleagues), PE-22-28 and related spadin analogs produced antidepressant-like effects with a rapid onset — days rather than the weeks conventional antidepressants take — together with increased hippocampal neurogenesis and synaptogenesis markers. That rapid-onset profile is the headline attraction, echoing the interest in other fast-acting antidepressant mechanisms.
Two limits define the honest reading. First, the record is concentrated in one research programme — consistent direction from a single group is weaker than independent replication. Second, and decisively, there are no human studies of any kind: no registered trial, no pharmacokinetics, no safety data. Rapid-acting antidepressant candidates are a notorious graveyard for translation, and animal behavioural-despair assays are weak stand-ins for human depression. PE-22-28 has cleared a preclinical bar that many later failures also cleared.
Mechanism (as proposed)
PE-22-28 is proposed to work exactly as spadin does — by blocking TREK-1, raising the excitability of serotonergic neurons and, downstream, promoting BDNF-associated neurogenesis and synaptogenesis. The shortening relative to spadin is intended to improve metabolic stability while preserving channel affinity. The mechanism is coherent and genetically anchored — but it was characterised largely within the same programme that reported the efficacy, and it has never been tested in a human.